

10/549323

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Frank STRIGGOW et al.

2005 Rec'd PCT/PTO 16 SEP 2005

Title: Use of Incense or Hydrogenation Products for Preventing  
and/or Treating a Cerebral Ischemia and/or Cerebral  
Traumatic LesionAppl. No.: Not Assigned  
(National Phase of PCT/EP04/02839)National Phase September 16, 2005  
Filing Date:

Examiner: Not Assigned

Art Unit: Not Assigned

Atty Docket No: LNK-007

**INFORMATION DISCLOSURE STATEMENT****MAIL STOP AMENDMENT**Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. Accordingly, no certification or fee is required.

JC05 Rec'd PCT/PTO 16 SEP 2005

20/549323

Note, the documents listed in the Form PTO-1449 were cited during the international phase of prosecution of the instant application. Copies of the foreign patent and non-patent literature references are enclosed herewith along with a copy of the international search report. However, in accordance with the revised procedures under 37 CFR 1.98(a)(2)(i), copies of the cited U.S. patent references have not been provided.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 50-2101.

Respectfully submitted,

Date: 09/16/05

By: Chalin A. Smith

SMITH PATENT CONSULTING, LLC  
P.O. Box 2726  
Alexandria, VA 22301

Name: Chalin A. Smith  
Title: Attorney for Applicant  
Registration No. 41,569

Tel: 703-549-7691  
Fax: 703-549-7692

**CUSTOMER NUMBER 31496**

**INFORMATION DISCLOSURE  
CITATION IN AN  
APPLICATION  
(PTO-1449)**

ATTY. DOCKET NO.  
**LNK-007**

SERIAL NO.  
Not Assigned  
(National Phase of  
PCT/EP04/02839)

**10/549323**

APPLICANT  
**F. STRIGGOW et al.**

NATIONAL PHASE FILING  
DATE  
**September 16, 2005**

GROUP  
**Not Assigned**

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,720,975	02-24-98	Etzel	424	464	
	6,280,751	08-28-01	Fletcher et al.	424	401	

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY/APPLICANT	CLASS	SUBCLASS	Translation

**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

	International Search Report issued in PCT/EP04/02839
	Wang, W, WPI Database No. XP-002291633, Derwent Publications Ltd. (1995) - Abstract only
	Kreck, C. et al., Versicherungsmedizin E.V. 1, Vol. 51, No. 3, pp. 122-127 (1999)
	Safayhi, H. et al., Pharmazeutische Zeitung, Vol. 142, No. 39, pp. 11-20 (1999)
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.